NewAmsterdam Pharma Operating Income Over Time
| NAMSW Stock | 20.00 0.55 2.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NewAmsterdam Pharma Performance and NewAmsterdam Pharma Correlation. NewAmsterdam | Build AI portfolio with NewAmsterdam Stock |
What growth prospects exist in Biotechnology sector? Can NewAmsterdam capture new markets? Factors like these will boost the valuation of NewAmsterdam Pharma. Anticipated expansion of NewAmsterdam directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each NewAmsterdam Pharma valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Investors evaluate NewAmsterdam Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NewAmsterdam Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause NewAmsterdam Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between NewAmsterdam Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewAmsterdam Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NewAmsterdam Pharma's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare NewAmsterdam Pharma and related stocks such as Scholar Rock Holding, Veracyte, and Ideaya Biosciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (50.7 M) | (54.5 M) | (86.9 M) | (129.9 M) | (134.4 M) | (171.3 M) | (252.1 M) | (226.8 M) | (215.5 M) |
| VCYT | (15.3 M) | (15.3 M) | (18.9 M) | (23.2 M) | (29 M) | (33.5 M) | (28.8 M) | (26.5 M) | (22.2 M) | (15.1 M) | (35.4 M) | (81.9 M) | (41.1 M) | (85.8 M) | 16.1 M | 14.5 M | 15.3 M |
| IDYA | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (36.4 M) | (44.3 M) | (35.3 M) | (50.3 M) | (62.5 M) | (134.4 M) | (327 M) | (294.3 M) | (279.6 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (65.4 M) | (108.2 M) | (170 M) | (157.4 M) | (156.6 M) | 9.8 M | (25.2 M) | (45.6 M) | (52.5 M) | (55.1 M) |
| ZLAB | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (38.5 M) | (51.4 M) | (141.8 M) | (203.2 M) | (301.8 M) | (700.1 M) | (404.4 M) | (366.6 M) | (282.1 M) | (253.9 M) | (266.6 M) |
| FOLD | (6.6 M) | (50.9 M) | (52.9 M) | (64.2 M) | (68.7 M) | (130.4 M) | (181.9 M) | (442 M) | (328.8 M) | (304 M) | (247 M) | (206.4 M) | (212.1 M) | (77.2 M) | 24.9 M | 22.4 M | 23.5 M |
| TARS | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (4.3 M) | (27 M) | (12.2 M) | (62.7 M) | (143.2 M) | (120.6 M) | (108.5 M) | (103.1 M) |
| IRON | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (34 M) | (30.9 M) | (47.5 M) | (91.1 M) | (129.7 M) | (116.7 M) | (110.9 M) |
| LEGN | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | (1.5 M) | (132.5 M) | (313.3 M) | (392.3 M) | (455.6 M) | (439.5 M) | (303.2 M) | (272.9 M) | (286.6 M) |
| MLYS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (18.7 M) | (31.5 M) | (84.7 M) | (192.4 M) | (173.2 M) | (164.5 M) |
NewAmsterdam Pharma and related stocks such as Scholar Rock Holding, Veracyte, and Ideaya Biosciences Operating Income description
Operating Income is the amount of profit realized from NewAmsterdam Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NewAmsterdam Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| NewAmsterdam Pharma | NAMSW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Gooimeer 2-35, Naarden, |
| Exchange | NASDAQ Exchange |
null 20.0
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.